NPORT-EX 2 hrtsvconfidential.htm PART F
Tema ETF Trust
            
Tema Cardiovascular and Metabolic ETF
            
Schedule of Investments
            
November 30, 2023 (Unaudited)
            
             
Investments
  
Number of Shares
    
Value
  
 COMMON STOCKS - 98.1%
            
 Biotechnology - 49.1%
            
Akero Therapeutics, Inc.*
    
6,204
    
$
103,855
  
Alnylam Pharmaceuticals, Inc.*
    
2,303
      
387,480
  
Amgen, Inc.
    
2,162
      
582,962
  
Arcturus Therapeutics Holdings, Inc.*
    
6,675
      
159,800
  
Arrowhead Pharmaceuticals, Inc.*
    
9,024
      
191,309
  
Ascendis Pharma A/S - ADR*^
    
2,914
      
292,653
  
Bridgebio Pharma, Inc.*
    
14,101
      
404,840
  
Crinetics Pharmaceuticals, Inc.*
    
10,387
      
330,203
  
Cytokinetics, Inc.*
    
5,499
      
184,107
  
Intellia Therapeutics, Inc.*
    
12,832
      
380,212
  
Ionis Pharmaceuticals, Inc.*
    
6,862
      
339,463
  
Madrigal Pharmaceuticals, Inc.*
    
1,458
      
296,411
  
Mereo Biopharma Group plc - ADR*^
    
122,952
      
256,970
  
Mineralys Therapeutics, Inc.*
    
18,471
      
123,017
  
Mirum Pharmaceuticals, Inc.*
    
5,734
      
183,889
  
Rocket Pharmaceuticals, Inc.*
    
15,040
      
350,883
  
Tenaya Therapeutics, Inc.*
    
47,893
      
90,039
  
Ultragenyx Pharmaceutical, Inc.*
    
8,319
      
323,193
  
Vertex Pharmaceuticals, Inc.*
    
1,739
      
617,015
  
Verve Therapeutics, Inc.*
    
10,623
      
119,827
  
Viking Therapeutics, Inc.*
    
15,652
      
191,267
  
Zealand Pharma A/S*^
    
5,076
      
249,032
  
             
6,158,427
  
 Health Care Equipment & Supplies - 22.8%
                
Boston Scientific Corp.*
    
5,452
      
304,712
  
Dexcom, Inc.*
    
4,372
      
505,053
  
Edwards Lifesciences Corp.*
    
4,982
      
337,331
  
Inari Medical, Inc.*
    
4,700
      
280,543
  
Insulet Corp.*
    
1,928
      
364,566
  
Masimo Corp.*
    
2,303
      
215,929
  
Medtronic plc - ADR ^
    
5,264
      
417,277
  
Omnicell, Inc.*
    
6,674
      
222,645
  
Shockwave Medical, Inc.*
    
1,222
      
213,300
  
             
2,861,356
  
 Insurance - 1.2%
                
Oscar Health, Inc., Class A *
    
17,249
      
146,617
  
 Life Sciences Tools & Services - 2.1%
                
West Pharmaceutical Services, Inc.
    
753
      
264,122
  
 Pharmaceuticals - 22.9%
                
Bayer AG^
    
6,956
      
237,444
  
Bristol-Myers Squibb Co.
    
5,828
      
287,787
  
Chugai Pharmaceutical Co., Ltd.^
    
12,267
      
431,736
  
Cymabay Therapeutics, Inc.*
    
11,703
      
223,878
  
Eli Lilly & Co.
    
1,034
      
611,135
  
Novartis AG^
    
3,713
      
360,912
  
Novo Nordisk A/S, Class B^
    
6,157
      
625,261
  
Structure Therapeutics, Inc. - ADR*^
    
1,598
      
88,993
  
             
2,867,146
  
TOTAL COMMON STOCKS (Cost $12,262,446)
            
12,297,668
  
                 
SHORT-TERM INVESTMENTS - 0.4%
                
Money Market Funds
                
First American Treausry Obligations Fund - Class X, 5.277% (a)
    
49,876
      
49,876
  
TOTAL MONEY MARKET FUNDS (Cost $49,876)
            
49,876
  
                 
TOTAL INVESTMENTS (Cost $12,312,322)  - 98.5%
            
12,347,544
  
OTHER ASSETS LESS LIABILITIES - 1.5%
            
187,497
  
NET ASSETS - 100.0%
          
$
12,535,041
  

* Non-income producing security.
          
^ Foreign security.
          
(a) 7-day net yield.
          
ADR - American Depositary Receipt
          
plc - Public Limited Company
          
           
The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.
Tema Cardiovascular and Metabolic ETF
    
November 30, 2023 (Unaudited)
    
ALLOCATION BY SECTOR
  
     
Sector
Percentage of
Total Net Assets
  
Health Care
96.9%
  
Financials
1.2%
  
Money Market Fund and Other Assets and Liabilities
1.9%
  
Total
100.0%
  
ALLOCATION BY COUNTRY
  
     
Country
Percentage of
Total Net Assets
  
United States
74.9%
  
Denmark
9.3%
  
Japan
3.4%
  
Ireland
3.3%
  
Switzerland
2.9%
  
United Kingdom
2.1%
  
Germany
1.9%
  
Cayman Islands
0.7%
  
Other(1)
1.5%
  
Total
100.0%
  
     
(1) Includes cash and net other assets (liabilities).
    
Tema ETF Trust
    
Tema Cardiovascular and Metabolic ETF
    
Notes to Quarterly Schedule of Investments
    
November 30, 2023 (Unaudited)
    
               
Investment Valuation
              
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
               
• Level 1 — Quoted prices in active markets for identical assets that the Fund's have the ability to access.
        
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).
               
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
               
The following is a summary of the inputs used to value the Fund's investments as of November 30, 2023:

Tema Cardiovascular and Metabolic ETF
  
Level 1
    
Level 2
    
Level 3
    
Total
  
Investments
                        
   Common Stocks *
  
$
12,297,668
    
$
-
    
$
-
    
$
12,297,668
  
   Money Market Fund
    
49,876
      
-
      
-
      
49,876
  
Total Investments
  
$
12,347,544
    
$
-
    
$
-
    
$
12,347,544
  
                                 
* See Schedule of Investments for segregation by industry.